MedTrace Logo

Individual Patient Expanded Access IND to Treat Polyneuropathy

NCT04064983 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-09-29

No results posted yet for this study

Summary

This Individual Patient Expanded Access IND has been created as requested by an 58-year-old man who suffers from Polyneuropathy due to Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin abnormalities (POEMS) Syndrome. The patient will receive 8 infusions of 200 million cells every four weeks during a 28-week period to relieve the symptoms of Polyneuropathy arising due to POEMS.

Conditions

  • Polyneuropathies

Interventions

BIOLOGICAL

HB-adMSCs

Hope Biosciences autologous adipose-derived mesenchymal stem cells

Sponsors & Collaborators

  • Hope Biosciences Research Foundation

    lead INDUSTRY

Principal Investigators

  • Thanh Cheng, MD · Hope Biosciences Stem Cell Research Foundation

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04064983 on ClinicalTrials.gov